脊柱关节炎靶向治疗暴露时长与癌症风险:法国全国队列研究
本研究基于法国医保数据库纳入56,591例启动靶向治疗的脊柱关节炎成人患者,中位随访5.0年。每年暴露超过6个月与总体癌症风险降低相关(wHR 0.86,95%CI 0.75-0.99),主要见于血液系统恶性肿瘤,累积暴露史与癌症风险无关。
要点
- 每年靶向治疗暴露>6个月与总体癌症风险降低相关(wHR 0.86)。
- 该负相关主要见于血液系统恶性肿瘤(wHR 0.65),实体瘤无统计学关联。
- 多年累积暴露轨迹与癌症风险无关。
核心结论
- 长期暴露于靶向治疗未增加脊柱关节炎患者的癌症风险。
- 每年暴露>6个月与较低的总体癌症风险相关,主要驱动于血液系统恶性肿瘤。
- 多年累积暴露与癌症风险无关。
研究设计与样本
- 法国全国队列研究,使用法国医保数据库识别2014年1月至2022年9月启动靶向治疗的成人脊柱关节炎患者。
- 排除既往癌症、HIV感染或器官移植者,随访自3个月延迟后开始至2024年12月。
- 暴露按年评估并分为每年≤6个月或>6个月,采用逆概率治疗和删失加权的Cox边际结构模型。
主要发现
- 共纳入56,591例患者(女性53.9%,平均年龄44±13岁,中位随访5.0年),发生1,224例癌症(实体瘤1,029例,血液系统116例,未分类79例)。
- 每年暴露>6个月对比≤6个月与总体癌症风险降低相关(wHR 0.86,95%CI 0.75-0.99)。
- 血液系统恶性肿瘤风险降低(wHR 0.65,95%CI 0.42-0.99),实体瘤无统计学关联(wHR 0.92,95%CI 0.79-1.07)。
- 累积暴露史与癌症风险无关。
临床怎么用
- 对于需长期靶向治疗的脊柱关节炎患者,持续每年>6个月的暴露未显示增加癌症风险。
- 临床决策中无需因癌症风险担忧而限制靶向治疗暴露时长超过每年6个月。
局限性
- 观察性设计可能残留混杂,暴露分组基于年度评估可能错分。
- 随访中位5.0年,不足以评估长期累积暴露的癌症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. METHODS: This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy (tumor necrosis factor inhibitors [TNFi], interleukin-17 inhibitors [IL-17i], IL-12/23i, IL-23i, JAK inhibitors [JAKi]) from January 2014 to September 2022. Patients with prior cancer, HIV infection, or organ transplantation were excluded. Follow-up began after a three-month delay and continued until December 2024. Exposure was assessed annually and classified as ≤6 or >6 months per year. Incident cancer was the primary outcome. Weighted Cox marginal structural models with inverse probability of treatment and censoring weights were used. A post hoc sensitivity analysis evaluated cumulative exposure trajectories over time. RESULTS: We included 56,591 patients (53.9% women; mean ± SD age 44 ± 13 years; median follow-up 5.0 years). During follow-up, 1,224 cancers occurred (1,029 solid, 116 hematological, 79 unclassified). Exposure >6 months versus ≤6 months was associated with a lower risk of overall cancer (weighted hazard ratio [wHR] 0.86, 95% confidence interval [CI] 0.75-0.99). In subgroup analyses, this association was observed for hematological malignancies (wHR 0.65, 95% CI 0.42-0.99) but not for solid cancers (wHR 0.92, 95% CI 0.79-1.07). Cumulative exposure history was not associated with cancer risk. CONCLUSION: In this nationwide study, prolonged exposure to targeted therapies was not associated with an increased cancer risk. Exposure >6 months per year was associated with a lower cancer risk, mainly for hematological malignancies, whereas cumulative exposure over multiple years was not associated with cancer risk.
引用
- Tankovic K, Claudepierre P, Vo TT, et al. Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database. Arthritis Rheumatol. 2026. PMID: 42605840. doi:10.1002/art.70297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。